HIGH GRADE SEROUS OVARIAN CANCER
Clinical trials for HIGH GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for HIGH GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: Rina-S trial launches
Disease control Recruiting nowThis study tests a new drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 764 participants will receive th…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 16, 2026 23:35 UTC
-
Virus therapy may Re-Sensitize ovarian cancer to chemo
Disease control Recruiting nowThis study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated May 16, 2026 23:32 UTC
-
New hope for hard-to-treat cancers? first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called azirkitug, alone or with other medicines, in people with advanced solid tumors like lung, head/neck, and other cancers. The goal is to find safe doses and check side effects. About 694 adults will take part at sites worldwide.
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New drug duo shows promise for Hard-to-Treat gynecological cancers
Disease control Recruiting nowThis study tests two drugs, VS-6766 and defactinib, in people with certain gynecological cancers that have come back. The goal is to see if the combination can shrink tumors and how safe it is. About 55 adults with specific gene mutations (RAS, BRAF, or NF1) will take part.
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug IDE034 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors…
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
Can a simple blood test predict ovarian cancer relapse?
Knowledge-focused Recruiting nowThis study is for women newly diagnosed with a common type of ovarian cancer. Researchers will collect blood samples before surgery, after chemotherapy, and during follow-up treatment to look for tumor DNA. The goal is to see if this DNA test can predict how well the maintenance …
Matched conditions: HIGH GRADE SEROUS OVARIAN CANCER
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC